SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpectra (unres) Regulatory News (SPSY)

Share Price Information for Spectra (unres) (SPSY)

Share Price is delayed by 15 minutes
Get Live Data
182.50    2.00 (1.11%)
Bid:
180.00
Ask:
185.00
Spread: 5.00 (2.778%)
Market Cap: £88.37m
SPSY Live PriceLast checked at - London Stock Exchange

Intraday Spectra (unres) Share Chart

Share Buyback Programme

25 Nov 2025 07:00

RNS Number : 8151I
Spectra Systems Corporation
25 November 2025
 

Spectra Systems Corporation

(The "Company" or "Spectra Systems")

Share Buyback Programme

Spectra Systems, a leader in machine-readable high speed banknote authentication, brand protection technologies and gaming security software, announces the launch of an initial share buyback programme of unrestricted common shares of US$0.01 each ("Common Shares") to repurchase up to US$350,000 worth of Common Shares (the "Buyback Programme"), effective from today.

The Board considers the Buyback Programme to be in the best interests of all shareholders, given the cash generative nature of the business and the surplus cash the Company holds. It is also consistent with the Board's desire to increase shareholder value/ returns.

The Company has appointed its broker, Zeus Capital Limited ("Zeus"), to manage the Buyback Programme to repurchase Ordinary Shares on its behalf and entered into an irrevocable and non-discretionary arrangement on 24 November 2025 with Zeus, to enable Zeus to conduct the Buyback Programme on a broker-managed basis. Zeus will make trading decisions in relation to the Buyback Programme independently of the Company, within certain defined parameters.

The Buyback Programme commences today and will end on the earlier of the date upon which the aggregate consideration paid for Common Shares reaches US$350,000 or 5 December 2025 (the "Buyback Period"). During the Buyback Period the Company has no power to invoke any changes to the authority and any purchases will be undertaken by Zeus, acting independently of, and uninfluenced by the Company.

Common Share repurchases will take place in open market transactions and may be made from time to time depending on market conditions, share price and trading volume. The Buyback Programme is in accordance with the Company's general authority to purchase its own shares under Delaware General Corporation Law. The price paid for Common Shares under the Buyback Programme will be no more than: a) 105 per cent. of the average trading price of the Ordinary Shares as derived from the middle market quotations for an Ordinary Share on the London Stock Exchange Daily Official List for the five trading days immediately preceding the date on which an Ordinary Share is contracted to be purchased; and b) £1.35.

Under the Buyback Programme, the repurchased shares will be cancelled.

The Buyback Programme will be conducted within the parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (each as in force in the UK from time to time, including where relevant pursuant to the Market Abuse (Amendment) (EU Exit) Regulations 2019.

The Company will make further announcements in due course following any share purchases conducted through the Buyback Programme.

Following this announcement, the issued share capital of the Company remains unchanged at:

· 47,758,431 shares in the unrestricted line ISIN number US84756T1060 (AIM:SPSY); and

· 542,258 shares in the Regulation S stock line ISIN number USU8457D1091 (AIM:SPSC)

Spectra Systems has no Shares in treasury, therefore 48,300,689 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The Company confirms that it currently has no unpublished price sensitive information.

Enquiries:

 

Spectra Systems Corporation 

Dr. Nabil Lawandy, Chief Executive Officer 

Tel: +1 (0)401 274 4700 

Zeus (Nominated Adviser and Joint Broker)

James Joyce / James Bavister (Investment Banking) 

Fraser Marshall (Corporate Broking) 

 

Allenby Capital Limited (Joint Broker) 

Nick Naylor/James Reeve (Corporate Finance) 

Amrit Nahal (Sales and Corporate Broking)

Tel: +44 (0)20 3829 5000

 

Tel: +44 (0)20 3328 5665 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPGBWGUPAPUC
Date   Source Headline
26th Jun 20233:22 pmRNSAnnual General Meeting Lack of Quorum
14th Jun 20237:00 amRNSUpdate on Development Contracts
30th May 20237:00 amRNSAppointment of Chief Financial Officer
25th Apr 20237:00 amRNSAdditional Sensor Services Contract Amendment
24th Apr 20237:00 amRNSResignation of Chief Financial Officer
19th Apr 20237:05 amRNSRemoval of Reg S restrictions from common stock
6th Apr 20237:00 amRNSExercise of Options
31st Mar 20235:14 pmRNSRemoval of Reg S restrictions from shares
21st Mar 202311:44 amRNSDividend Record Date
20th Mar 20237:00 amRNSAudited results for year ended 31 December 2022
16th Mar 20234:35 pmRNSExercise of Options
13th Mar 20237:00 amRNSNotice of Results
6th Mar 202310:39 amRNSRemoval of Reg S restrictions from common stock
11th Oct 20226:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSContract Amendment to a Central Bank
21st Sep 20227:00 amRNSExercise of Options
12th Sep 20227:05 amRNSAppointment of Non-Executive Director
12th Sep 20227:00 amRNSInterim Results for Six Months Ended 30 June 2022
16th Aug 20227:00 amRNSFirst Banknote Disinfection System Sold
15th Aug 20227:00 amRNSNew Central Bank Contract Amendment
28th Jul 20227:00 amRNSShare Buy-Back
1st Jul 20222:31 pmRNSShare Buy-Back
28th Jun 20227:00 amRNSShare Buy-Back
15th Jun 20227:00 amRNSAdditional Central Bank Development Revenues
14th Jun 20227:00 amRNSAppointment of Chief Financial Officer
13th Jun 20227:00 amRNSUpdate regarding Solaris
13th Jun 20227:00 amRNSAnnual General Meeting Update
25th May 20227:00 amRNSExercise of Options and Director/PDMR Shareholding
20th May 20228:44 amRNSRemoval of Regulation S restrictions from shares
20th May 20228:41 amRNSResignation of Chief Financial Officer
3rd May 20227:00 amRNSPosting of Annual Report & Notice of AGM
6th Apr 20221:36 pmRNSRemoval of Reg S restrictions from common stock
28th Mar 20227:00 amRNSGrant of Share Options
21st Mar 20227:00 amRNSResults twelve months ended 31 December 2021
24th Feb 20227:00 amRNSSpectra Introduces Covert Polymer Substrate
24th Jan 20227:00 amRNSNew contract awards
21st Jan 20227:00 amRNSExercise of Options
6th Dec 20217:00 amRNSNew K-cup Orders in Q4 Exceed Expectations
2nd Nov 20213:37 pmRNSExercise of Options
1st Nov 20217:00 amRNSNew Lottery Contract Win
25th Oct 20214:18 pmRNSRemoval of Regulation S restrictions
11th Oct 20217:00 amRNSLarge Central Bank Order
27th Sep 20217:00 amRNSAppointment of Allenby Capital as joint broker
13th Sep 202110:27 amRNSHolding(s) in Company
25th Aug 202111:23 amRNSRemoval of Regulation S restrictions
21st Jul 20217:00 amRNSBanknote cleaning system also deactivates Covid-19
14th Jun 20217:00 amRNSAnnual General Meeting Update
17th May 20215:12 pmRNSShare Buy-Back
7th May 20214:49 pmRNSShare Buy-Back
6th May 20212:58 pmRNSShare Buy-Back

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.